Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
29 hedge funds and large institutions have $48.4M invested in Sinovac Biotech, Ltd in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 12 reducing their positions, and 5 closing their positions.
26% more call options, than puts
Call options by funds: $482K | Put options by funds: $384K
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $58.8M → $48.4M (-$10.4M)
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSP
Sapphire Star Partners
Redmond,
Washington
|
+$763K |
| 2 |
YMRC
Yorktown Management & Research Company
Forest,
Virginia
|
+$509K |
| 3 |
NA
Navellier & Associates
Reno,
Nevada
|
+$251K |
| 4 |
Millennium Management
New York
|
+$80.2K |
| 5 |
Morgan Stanley
New York
|
+$42.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$922K |
| 2 |
Renaissance Technologies
New York
|
-$834K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$827K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$678K |
| 5 |
SIM
Spark Investment Management
New York
|
-$208K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FGAM
26
Financial Gravity Asset Management
Lakeway,
Texas
| $3K | +$2.56K | +325 | +241% |
|
|
GWM
27
Geneos Wealth Management
Englewood,
Colorado
| $1K | – | – | – |
|
|
GC
28
Guggenheim Capital
Chicago,
Illinois
| – | -$179K | -20,840 | Closed |
|
29
Two Sigma Investments
New York
| – | -$158K | -18,302 | Closed |
|
|
DAM
30
DLD Asset Management
New York
| – | -$86K | -10,000 | Closed |
|
|
PCM
31
Prelude Capital Management
New York
| – | -$86K | -10,000 | Closed |
|
32
SEI Investments
Oaks,
Pennsylvania
| – | +$8 | +1 | New |
|
|
CF
33
Centaurus Financial
Anaheim,
California
| – | +$94 | +12 | New |
|
SVA Hedge Fund Activity: Q2 2018 in Review
29 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2018, worth a combined $48.4M — down 18% from $58.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SVA positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 12 trimmed.
The largest buyer was Sapphire Star Partners, opening a new position worth an estimated $763K. The largest seller was Freedom Investment Management, cutting an estimated $922K.
- 29 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $48.4M of Sinovac Biotech, Ltd stock for Q2 2018, down 18% quarter-over-quarter.
- 6 funds opened new Sinovac Biotech, Ltd positions in Q2 2018 and 5 closed out, a net change of +1 holder.
- The largest Sinovac Biotech, Ltd buyer in Q2 2018 was Sapphire Star Partners, an estimated $763K added.
- The largest Sinovac Biotech, Ltd seller in Q2 2018 was Freedom Investment Management, an estimated $922K sold.
Based on aggregated 13F filings for Q2 2018.